Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Free Report) - Equities research analysts at Leerink Partnrs issued their FY2027 earnings per share (EPS) estimates for Cullinan Therapeutics in a note issued to investors on Monday, October 28th. Leerink Partnrs analyst A. Berens anticipates that the company will post earnings of $0.54 per share for the year. The consensus estimate for Cullinan Therapeutics' current full-year earnings is ($3.20) per share.
Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.73) by ($0.02).
CGEM has been the subject of a number of other research reports. HC Wainwright reissued a "buy" rating and set a $28.00 price objective on shares of Cullinan Therapeutics in a research report on Wednesday, October 16th. UBS Group began coverage on Cullinan Therapeutics in a report on Thursday, October 24th. They set a "buy" rating and a $30.00 price target for the company. Finally, Wedbush reaffirmed an "outperform" rating and issued a $36.00 price objective on shares of Cullinan Therapeutics in a research note on Wednesday, September 18th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $31.67.
View Our Latest Report on Cullinan Therapeutics
Cullinan Therapeutics Price Performance
Shares of CGEM traded down $0.70 on Wednesday, reaching $16.22. The company's stock had a trading volume of 196,843 shares, compared to its average volume of 658,403. Cullinan Therapeutics has a 12-month low of $7.64 and a 12-month high of $30.19. The stock has a market capitalization of $940.39 million, a P/E ratio of -5.30 and a beta of -0.13. The stock's 50 day simple moving average is $17.21 and its two-hundred day simple moving average is $19.17.
Hedge Funds Weigh In On Cullinan Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of CGEM. SG Americas Securities LLC grew its holdings in Cullinan Therapeutics by 757.2% during the 2nd quarter. SG Americas Securities LLC now owns 85,172 shares of the company's stock valued at $1,485,000 after buying an additional 75,236 shares in the last quarter. Marshall Wace LLP grew its holdings in shares of Cullinan Therapeutics by 2,416.9% in the second quarter. Marshall Wace LLP now owns 1,184,037 shares of the company's stock valued at $20,650,000 after purchasing an additional 1,136,993 shares in the last quarter. E Fund Management Co. Ltd. bought a new stake in Cullinan Therapeutics in the second quarter worth $1,305,000. Bank of New York Mellon Corp raised its stake in Cullinan Therapeutics by 46.4% during the second quarter. Bank of New York Mellon Corp now owns 137,997 shares of the company's stock valued at $2,407,000 after purchasing an additional 43,757 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in Cullinan Therapeutics by 22.2% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 17,269 shares of the company's stock valued at $294,000 after purchasing an additional 3,134 shares in the last quarter. Institutional investors own 86.31% of the company's stock.
Insider Activity
In related news, insider Jennifer Michaelson sold 8,000 shares of the stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $18.09, for a total transaction of $144,720.00. Following the completion of the sale, the insider now owns 115,942 shares in the company, valued at approximately $2,097,390.78. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 6.07% of the company's stock.
About Cullinan Therapeutics
(
Get Free Report)
Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.
Further Reading
Before you consider Cullinan Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cullinan Therapeutics wasn't on the list.
While Cullinan Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
